Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPAR𝛾 and PPAR𝛾 have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPAR𝛾 agonists also regul...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/520465 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555351946297344 |
|---|---|
| author | Mark A. Deeg Meng H. Tan |
| author_facet | Mark A. Deeg Meng H. Tan |
| author_sort | Mark A. Deeg |
| collection | DOAJ |
| description | Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPAR𝛾 and PPAR𝛾 have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPAR𝛾 agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPAR𝛾 agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents |
| format | Article |
| id | doaj-art-acef94914b6e4c75ae4c3f1113409cde |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-acef94914b6e4c75ae4c3f1113409cde2025-02-03T05:48:28ZengWileyPPAR Research1687-47571687-47652008-01-01200810.1155/2008/520465520465Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical StudiesMark A. Deeg0Meng H. Tan1Endocrine Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USAEndocrine Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USAPeroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPAR𝛾 and PPAR𝛾 have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPAR𝛾 agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPAR𝛾 agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agentshttp://dx.doi.org/10.1155/2008/520465 |
| spellingShingle | Mark A. Deeg Meng H. Tan Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies PPAR Research |
| title | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| title_full | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| title_fullStr | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| title_full_unstemmed | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| title_short | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| title_sort | pioglitazone versus rosiglitazone effects on lipids lipoproteins and apolipoproteins in head to head randomized clinical studies |
| url | http://dx.doi.org/10.1155/2008/520465 |
| work_keys_str_mv | AT markadeeg pioglitazoneversusrosiglitazoneeffectsonlipidslipoproteinsandapolipoproteinsinheadtoheadrandomizedclinicalstudies AT menghtan pioglitazoneversusrosiglitazoneeffectsonlipidslipoproteinsandapolipoproteinsinheadtoheadrandomizedclinicalstudies |